AlloVir (ALVR) Competitors

$4.92 -0.20 (-3.91%)

As of 05/22/2026

ALVR vs. ONCY, LONA, AARD, PMN, and UPXI

Should you buy AlloVir stock or one of its competitors? MarketBeat compares AlloVir with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with AlloVir include Oncolytics Biotech (ONCY), Athira Pharma (LONA), Aardvark Therapeutics (AARD), Promis Neurosciences (PMN), and Upexi (UPXI). These companies are all part of the "pharmaceutical products" industry.

How does AlloVir compare to Oncolytics Biotech?

AlloVir (NASDAQ:ALVR) and Oncolytics Biotech (NASDAQ:ONCY) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends and valuation.

In the previous week, Oncolytics Biotech had 2 more articles in the media than AlloVir. MarketBeat recorded 2 mentions for Oncolytics Biotech and 0 mentions for AlloVir. AlloVir's average media sentiment score of 0.00 equaled Oncolytics Biotech'saverage media sentiment score.

Company	Overall Sentiment
AlloVir	Neutral
Oncolytics Biotech	Neutral

AlloVir's return on equity of -71.03% beat Oncolytics Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AlloVir	N/A	-71.03%	-61.27%
Oncolytics Biotech	N/A	-14,442.84%	-321.54%

Oncolytics Biotech has a consensus target price of $8.50, suggesting a potential upside of 950.03%. Given Oncolytics Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Oncolytics Biotech is more favorable than AlloVir.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Oncolytics Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Oncolytics Biotech is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A
Oncolytics Biotech	N/A	N/A	-$28.76M	-$0.31	N/A

AlloVir has a beta of 0.63, indicating that its share price is 37% less volatile than the broader market. Comparatively, Oncolytics Biotech has a beta of 1.02, indicating that its share price is 2% more volatile than the broader market.

66.1% of AlloVir shares are owned by institutional investors. Comparatively, 6.8% of Oncolytics Biotech shares are owned by institutional investors. 32.1% of AlloVir shares are owned by company insiders. Comparatively, 0.1% of Oncolytics Biotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Oncolytics Biotech beats AlloVir on 8 of the 13 factors compared between the two stocks.

How does AlloVir compare to Athira Pharma?

Athira Pharma (NASDAQ:LONA) and AlloVir (NASDAQ:ALVR) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

57.1% of Athira Pharma shares are held by institutional investors. Comparatively, 66.1% of AlloVir shares are held by institutional investors. 25.7% of Athira Pharma shares are held by insiders. Comparatively, 32.1% of AlloVir shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Athira Pharma's average media sentiment score of 0.00 equaled AlloVir'saverage media sentiment score.

Company	Overall Sentiment
Athira Pharma	Neutral
AlloVir	Neutral

AlloVir's return on equity of -71.03% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Athira Pharma	N/A	-381.01%	-225.74%
AlloVir	N/A	-71.03%	-61.27%

Athira Pharma is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athira Pharma	N/A	N/A	-$105.61M	-$5.21	N/A
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A

Athira Pharma has a beta of 1.98, suggesting that its stock price is 98% more volatile than the broader market. Comparatively, AlloVir has a beta of 0.63, suggesting that its stock price is 37% less volatile than the broader market.

Athira Pharma currently has a consensus target price of $10.00, suggesting a potential downside of 3.19%. Given Athira Pharma's stronger consensus rating and higher possible upside, equities analysts plainly believe Athira Pharma is more favorable than AlloVir.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Athira Pharma beats AlloVir on 6 of the 11 factors compared between the two stocks.

How does AlloVir compare to Aardvark Therapeutics?

Aardvark Therapeutics (NASDAQ:AARD) and AlloVir (NASDAQ:ALVR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, media sentiment, profitability, analyst recommendations, institutional ownership and valuation.

Aardvark Therapeutics is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A

In the previous week, Aardvark Therapeutics had 4 more articles in the media than AlloVir. MarketBeat recorded 4 mentions for Aardvark Therapeutics and 0 mentions for AlloVir. AlloVir's average media sentiment score of 0.00 beat Aardvark Therapeutics' score of -0.14 indicating that AlloVir is being referred to more favorably in the news media.

Company	Overall Sentiment
Aardvark Therapeutics	Neutral
AlloVir	Neutral

Aardvark Therapeutics has a beta of 5.11, suggesting that its stock price is 411% more volatile than the broader market. Comparatively, AlloVir has a beta of 0.63, suggesting that its stock price is 37% less volatile than the broader market.

Aardvark Therapeutics' return on equity of -61.71% beat AlloVir's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aardvark Therapeutics	N/A	-61.71%	-56.29%
AlloVir	N/A	-71.03%	-61.27%

66.1% of AlloVir shares are owned by institutional investors. 32.1% of AlloVir shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Aardvark Therapeutics presently has a consensus price target of $19.70, suggesting a potential upside of 333.92%. Given Aardvark Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Aardvark Therapeutics is more favorable than AlloVir.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.46
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Aardvark Therapeutics beats AlloVir on 10 of the 14 factors compared between the two stocks.

How does AlloVir compare to Promis Neurosciences?

AlloVir (NASDAQ:ALVR) and Promis Neurosciences (NASDAQ:PMN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, risk, valuation and dividends.

AlloVir has a beta of 0.63, indicating that its share price is 37% less volatile than the broader market. Comparatively, Promis Neurosciences has a beta of -0.2, indicating that its share price is 120% less volatile than the broader market.

66.1% of AlloVir shares are held by institutional investors. Comparatively, 50.1% of Promis Neurosciences shares are held by institutional investors. 32.1% of AlloVir shares are held by insiders. Comparatively, 1.5% of Promis Neurosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Promis Neurosciences is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A
Promis Neurosciences	N/A	N/A	-$39.72M	-$14.51	N/A

In the previous week, Promis Neurosciences had 10 more articles in the media than AlloVir. MarketBeat recorded 10 mentions for Promis Neurosciences and 0 mentions for AlloVir. Promis Neurosciences' average media sentiment score of 1.00 beat AlloVir's score of 0.00 indicating that Promis Neurosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
AlloVir	Neutral
Promis Neurosciences	Positive

Promis Neurosciences has a consensus target price of $26.50, suggesting a potential upside of 141.35%. Given Promis Neurosciences' stronger consensus rating and higher probable upside, analysts plainly believe Promis Neurosciences is more favorable than AlloVir.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Promis Neurosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

AlloVir's return on equity of -71.03% beat Promis Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AlloVir	N/A	-71.03%	-61.27%
Promis Neurosciences	N/A	-237.99%	-151.04%

Summary

Promis Neurosciences beats AlloVir on 8 of the 14 factors compared between the two stocks.

How does AlloVir compare to Upexi?

Upexi (NASDAQ:UPXI) and AlloVir (NASDAQ:ALVR) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, media sentiment, analyst recommendations, dividends and earnings.

Upexi currently has a consensus target price of $8.33, indicating a potential upside of 521.89%. Given Upexi's stronger consensus rating and higher possible upside, analysts plainly believe Upexi is more favorable than AlloVir.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Upexi	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Upexi has a beta of -0.32, indicating that its share price is 132% less volatile than the broader market. Comparatively, AlloVir has a beta of 0.63, indicating that its share price is 37% less volatile than the broader market.

5.7% of Upexi shares are held by institutional investors. Comparatively, 66.1% of AlloVir shares are held by institutional investors. 9.0% of Upexi shares are held by insiders. Comparatively, 32.1% of AlloVir shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Upexi had 1 more articles in the media than AlloVir. MarketBeat recorded 1 mentions for Upexi and 0 mentions for AlloVir. Upexi's average media sentiment score of 0.59 beat AlloVir's score of 0.00 indicating that Upexi is being referred to more favorably in the media.

Company	Overall Sentiment
Upexi	Positive
AlloVir	Neutral

AlloVir has a net margin of 0.00% compared to Upexi's net margin of -874.00%. Upexi's return on equity of -66.70% beat AlloVir's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Upexi	-874.00%	-66.70%	-19.56%
AlloVir	N/A	-71.03%	-61.27%

Upexi has higher revenue and earnings than AlloVir. Upexi is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Upexi	$15.81M	5.95	-$13.68M	-$0.62	N/A
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A

Summary

Upexi beats AlloVir on 11 of the 16 factors compared between the two stocks.

Get AlloVir News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALVR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALVR vs. The Competition

Export

Metric	AlloVir	Biological Products Industry	Medical Sector	NASDAQ Exchange
Market Cap	$24.81M	$309.61M	$6.46B	$12.34B
Dividend Yield	N/A	N/A	2.76%	5.28%
P/E Ratio	-0.24	N/A	21.22	25.65
Price / Sales	N/A	189.70	553.92	86.28
Price / Cash	N/A	22.44	43.49	56.67
Price / Book	0.17	4.77	10.37	7.14
Net Income	-$190.42M	-$132.96M	$3.57B	$335.98M
7 Day Performance	3.80%	2.45%	6.40%	4.15%
1 Month Performance	-19.48%	31.23%	3.52%	2.54%
1 Year Performance	76.34%	77.59%	34.02%	35.05%

AlloVir Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALVR AlloVir	N/A	$4.92 -3.9%	N/A	+76.3%	$24.81M	N/A	N/A	110	High Trading Volume
ONCY Oncolytics Biotech	2.6223 of 5 stars	$0.78 -3.1%	$8.50 +996.8%	+93.5%	$95.50M	N/A	N/A	30
LONA Athira Pharma	1.5606 of 5 stars	$10.09 -0.4%	$10.00 -0.9%	N/A	$95.16M	N/A	N/A	40
AARD Aardvark Therapeutics	3.0559 of 5 stars	$4.37 +0.2%	$19.70 +350.8%	-56.8%	$95.12M	N/A	N/A	18
PMN Promis Neurosciences	3.7003 of 5 stars	$10.65 +2.0%	$26.50 +148.8%	-13.0%	$93.58M	N/A	N/A	5	News Coverage Positive News Analyst Revision Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALVR) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AlloVir (ALVR) Competitors

ALVR vs. ONCY, LONA, AARD, PMN, and UPXI

How does AlloVir compare to Oncolytics Biotech?

Summary

How does AlloVir compare to Athira Pharma?

Summary

How does AlloVir compare to Aardvark Therapeutics?

Summary

How does AlloVir compare to Promis Neurosciences?

Summary

How does AlloVir compare to Upexi?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALVR vs. The Competition

AlloVir Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AlloVir (ALVR) Competitors

ALVR vs. ONCY, LONA, AARD, PMN, and UPXI

How does AlloVir compare to Oncolytics Biotech?

Does the media prefer ALVR or ONCY?

Is ALVR or ONCY more profitable?

Do analysts recommend ALVR or ONCY?

Which has preferable earnings and valuation, ALVR or ONCY?

Which has more volatility & risk, ALVR or ONCY?

Do institutionals & insiders have more ownership in ALVR or ONCY?

Summary

How does AlloVir compare to Athira Pharma?

Do institutionals and insiders hold more shares of LONA or ALVR?

Does the media prefer LONA or ALVR?

Is LONA or ALVR more profitable?

Which has stronger valuation and earnings, LONA or ALVR?

Which has more volatility & risk, LONA or ALVR?

Do analysts rate LONA or ALVR?

Summary

How does AlloVir compare to Aardvark Therapeutics?

Which has stronger earnings and valuation, AARD or ALVR?

Does the media refer more to AARD or ALVR?

Which has more volatility & risk, AARD or ALVR?

Is AARD or ALVR more profitable?

Do institutionals & insiders hold more shares of AARD or ALVR?

Do analysts prefer AARD or ALVR?

Summary

How does AlloVir compare to Promis Neurosciences?

Which has more volatility and risk, ALVR or PMN?

Do institutionals and insiders have more ownership in ALVR or PMN?

Which has stronger valuation and earnings, ALVR or PMN?

Does the media favor ALVR or PMN?

Do analysts prefer ALVR or PMN?

Is ALVR or PMN more profitable?

Summary

How does AlloVir compare to Upexi?

Do analysts recommend UPXI or ALVR?

Which has more volatility & risk, UPXI or ALVR?

Do insiders and institutionals believe in UPXI or ALVR?

Does the media refer more to UPXI or ALVR?

Is UPXI or ALVR more profitable?

Which has stronger valuation and earnings, UPXI or ALVR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALVR vs. The Competition

AlloVir Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools